ArticleWorld journal of pediatrics : WJP2026
Asparaginase methylation and childhood obesity: cross-tissue patterns and parent-child concordance in a prospective cohort.
Article in World journal of pediatrics : WJP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEarly-life epigenetic mechanisms may contribute to the developmental programming of childhood obesity. We aimed to examine whether placental asparaginase (ASPG) DNA methylation (DNAm) is associated with adiposity at 6 years of age and to explore its cross-tissue patterns and parent-child concordance.
methodsIn a prospective birth cohort, placental ASPG DNAm was quantified by pyrosequencing and related to anthropometric and cardiometabolic outcomes in children at 6 years (n = 180). DNAm was also measured in child peripheral blood (n = 127) and in maternal and paternal blood samples during pregnancy (n = 44).
resultsIncreased placental ASPG DNAm was associated with increased adiposity and cardiometabolic markers at 6 years and increased odds of overweight/obesity [odds ratio (OR) = 1.06, 95% confidence interval (CI) = 1.01-1.11, P = 0.01]. Similar associations were observed for child blood (OR = 1.19, 95% CI = 1.04-1.36, P = 0.01), although these analyses were cross-sectional. Placental and child DNAm levels were positively correlated (r = 0.40, P < 0.01), and maternal-child DNAm was concordant (r = 0.48, P < 0.01), although the parental analyses were exploratory and based on a limited sample size (n = 44).
conclusionsASPG DNAm is associated with childhood adiposity and shows cross-tissue and parent-child concordance, suggesting its potential role as an early-life epigenetic marker associated with metabolic risk. Given the modest effect sizes and exploratory nature of some analyses, these findings warrant cautious interpretation and require replication in independent cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.